share_log

歌礼制药-B(01672.HK):国家药监局批准开展ASC10治疗呼吸道合胞病毒感染IIa期临床试验

Geli Pharmaceutical-B (01672.HK): The National Drug Administration approved ASC10 for the treatment of respiratory syncytial virus infection phase IIa clinical trial

Gelonghui Finance ·  May 8, 2023 16:45

Gelonghui May 8th 丨Geli Pharmaceutical-B (01672.HK) announced that China's National Drug Administration (“China Drug Administration”) has approved the launch of a phase IIa clinical trial of ASC10 for the treatment of respiratory syncytial virus (RSV) infection. Based on available data, a randomized, double-blind, placebo-controlled phase IIa study with ASC10 was selected at a dose of 800 mg twice daily to evaluate the antiviral activity, safety, tolerability, and pharmacokinetics of ASC10 tablets in patients with mild and moderate respiratory syncytial virus infections. In January 2023, Colley received approval from the US Food and Drug Administration to conduct a phase IIa clinical trial of ASC10 for the treatment of respiratory syncytial virus infection.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment